Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Ibio ( (IBIO) ) has provided an announcement.
iBio, Inc. announced an update to its corporate presentation, highlighting the development of an antibody that inhibits Activin E, a therapeutic target for cardiometabolic disorders and obesity. Utilizing its patented machine-learning antibody engine, iBio aims to enhance its industry positioning by demonstrating strong preclinical results and advancing its pipeline for future clinical applications, potentially impacting stakeholders by offering innovative treatments for obesity and related conditions.
More about Ibio
iBio, Inc. is a biotechnology company that focuses on developing antibodies for cardiometabolic disorders and obesity through its AI-driven antibody discovery platform. The company collaborates with partners and uses its proprietary technology to target challenging drug targets, including antibodies targeting the Activin E protein.
YTD Price Performance: 12.40%
Average Trading Volume: 113,516
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $24.89M
Learn more about IBIO stock on TipRanks’ Stock Analysis page.
